Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27828766 | 0.99 | GAA (0.54) | LMNAGAATSHRALDH1A1MEN1 | |
| SCHEMBL17220302 | 0.99 | GAA (0.54) | LMNAGAATSHRALDH1A1MEN1 | |
| SCHEMBL5994789 | 0.84 | LMNA (0.49) | LMNAGAATSHRALDH1A1MEN1 | |
| SCHEMBL6980126 | 0.83 | AGTR2 (0.52) | DPP4 | |
| SCHEMBL19497216 | 0.83 | GAA (0.56) | LMNAGAATSHRALDH1A1MEN1 | |
| SCHEMBL9912127 | 0.83 | GAA (0.56) | LMNAGAATSHRALDH1A1MEN1 | |
| SCHEMBL9912125 | 0.83 | GAA (0.56) | LMNAGAATSHRALDH1A1MEN1 | |
| SCHEMBL8520410 | 0.83 | LMNA (0.51) | LMNAGAATSHRALDH1A1MEN1 | |
| SCHEMBL13014753 | 0.83 | KCNH2 (0.49) | LMNAGAATSHRALDH1A1MEN1 | |
| SCHEMBL13570514 | 0.82 | F2 (0.53) | ALDH1A1ERAP2ERAP1LNPEPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | LMNA 3118/4885GAA 223/4885TSHR 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.